Search

Your search keyword '"Kanazu, M."' showing total 93 results

Search Constraints

Start Over You searched for: Author "Kanazu, M." Remove constraint Author: "Kanazu, M."
93 results on '"Kanazu, M."'

Search Results

3. 64P Clinical benefit of platinum doublet therapy for elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the national hospital organization in Japan

5. LBA66 Afatinib versus chemotherapy for treatment-naïve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation: A phase III study (ACHILLES/TORG1834)

7. 1375P Predicting chemotherapy toxicity in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the national hospital organization in Japan

9. Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan

10. Predicting chemotherapy toxicity in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan

11. Prognostic impact of metastatic sites for pembrolizumab efficacy as first-line therapy in patients with PD-L1 tumour proportion score (TPS) ≥ 50% advanced non-small cell lung cancer: A retrospective multicenter study

12. The efficacy and safety of pembrolizumab as a first-line therapy in PD-L1 50% positive advanced NSCLC (HOPE-001)

13. Clinical outcomes in non–small cell lung cancer patients with ultra-high expression of programmed death ligand-1 treated with pembrolizumab as first-line therapy: A retrospective multicenter cohort study

14. Association between early immune-related adverse events and clinical outcomes in patients with advanced non-small cell lung cancer treated with pembrolizumab as first-line therapy: A retrospective multicenter cohort study

20. 1514P - Prognostic impact of metastatic sites for pembrolizumab efficacy as first-line therapy in patients with PD-L1 tumour proportion score (TPS) ≥ 50% advanced non-small cell lung cancer: A retrospective multicenter study

26. Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC.

27. Clinical benefit of platinum doublet combination therapy in older adults with advanced non-small cell lung cancer: A prospective multicenter study by the National Hospital Organization in Japan.

28. Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC.

29. Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility.

30. Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study.

31. Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01).

32. Predicting systemic therapy toxicity in older adult patients with advanced non-small cell lung cancer: A prospective multicenter study of National Hospital Organization in Japan.

33. Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis.

34. Non-small cell lung cancer with tumor proportion score > 90% could increase the risk of severe immune-related adverse events in first-line treatments with immune checkpoint inhibitors: A retrospective single-center study.

35. Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study.

36. Histologic transformation of epidermal growth factor receptor-mutated lung cancer.

37. Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002.

38. Bronchial ethanol injection therapy for airway obstruction in lung cancer patients.

39. Expectoration of tonsillar metastasis of pulmonary pleomorphic carcinoma after pseudoprogression: A case report.

40. Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study.

41. EGFR-mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib.

42. Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study.

43. Effectiveness of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study.

44. Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: A retrospective cohort study.

45. Treatment Rationale and Design of a Phase III Study of Afatinib or Chemotherapy in Patients with Non-small-cell Lung Cancer Harboring Sensitizing Uncommon Epidermal Growth Factor Receptor Mutations (ACHILLES/TORG1834).

47. Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.

48. Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab.

49. Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.

50. Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer.

Catalog

Books, media, physical & digital resources